Shares of Moderna Inc. MRNA, +10.92% soared 9.4% in trading on Wednesday after the Food and Drug Administration said children between the ages of 6 and 17 years old can now get the bivalent COVID-19 booster developed by the company. The regulator also said that children between the ages of 5 and 11 years old can get the updated BioNTech SE BNTX, +6.83% /Pfizer Inc. PFE, +1.26% shot. The bivalent vaccines are designed to better protect against omicron, including the BA.4 and BA.5 subvariants. Moderna’s stock has declined 48.3% this year, while the broader S&P 500 SPX, +0.22% is down 24.7%.
